CheckMate 078: Patient-Reported Outcomes (PROs) With Nivolumab vs Docetaxel in Advanced Non-Small Cell Lung Cancer (NSCLC)

被引：0
|
作者：
Wu, Y. [1 ,2 ]
Chang, J. [3 ]
Zhang, L. [4 ]
Tu, H. [1 ,2 ]
Wu, L. [5 ]
Feng, J. [6 ]
Lu, S. [7 ]
Zhou, C. [8 ]
Wang, J. [9 ,10 ]
Mok, T. [11 ]
Taylor, F. [12 ]
Mossman, B. [12 ]
Penrod, J. [13 ]
Lawrance, R. [14 ]
Blum, S. [13 ]
Wang, P. F. [13 ]
Cheng, Y. [15 ]
机构：
[1] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
[2] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China
[3] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[4] Sun Yat Sen Univ, Guangzhou, Guangdong, Peoples R China
[5] Hunan Canc Hosp, Changsha, Hunan, Peoples R China
[6] Jiangsu Canc Hosp, Nanjing, Jiangsu, Peoples R China
[7] Shanghai Jiao Tong Univ Shanghai, Shanghai Chest Hosp, Shanghai Lung Canc Ctr, Shanghai, Peoples R China
[8] Shanghai Pulm Hosp, Shang, Peoples R China
[9] Chinese Acad Med Sci, Natl Canc Ctr, Natl Clin Res Ctr Canc, Canc Hosp, Beijing, Peoples R China
[10] Peking Union Med Coll, Beijing, Peoples R China
[11] Chinese Univ Hong Kong, Shatin, Hong Kong, Peoples R China
[12] Adelphi Values, Boston, MA USA
[13] Bristol Myers Squibb, Princeton, NJ USA
[14] Adelphi Values, Bollington, England
[15] Jilin Canc Hosp, Changchun, Jilin, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 12期
关键词：
Advanced NSCLC; Nivolumab; Docetaxel; Patient-Reported Outcomes;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OA10
引用
收藏
页码：S1047 / S1048
页数：2
相关论文
共 50 条
  • [31] Impact of of Nivolumab versus Docetaxel on Health-Related Quality of Life and Symptoms in Patients with Advanced Squamous Non-Small Cell Lung Cancer: Results from the CheckMate 017 Study
    Reck, Martin
    Taylor, Fiona
    Penrod, John R.
    DeRosa, Michael
    Morrissey, Laura
    Dastani, Homa
    Orsini, Lucinda
    Gralla, Richard J.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (02) : 194 - 204
  • [32] Clinical and Plasma Biomarkers for Disease Control with Nivolumab Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC)
    Daher, Sameh
    Lawrence, Yaacov
    Dudnik, Elizabeth
    Hanovich, Ekaterina
    Urban, Damien
    Peled, Nir
    Navon, Rossie
    Leibowitz-Amit, Raya
    Hammerman, Ariel
    Battat, Erez
    Bar, Jair
    Onn, Amir
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1307 - S1307
  • [33] Analysis of Early Survival in Patients with Advanced Non-Squamous NSCLC Treated with Nivolumab vs Docetaxel in CheckMate 057
    Peters, Solange
    Cappuzzo, Frederico
    Horn, Leora
    Paz-Ares, Luis
    Borghaei, Hossein
    Barlesi, Fabrice
    Steins, Martin
    Felip, Enriqueta
    Spigel, David
    Dorange, Cecile
    Lu, Haolan
    Healey, Diane
    Sanchez, Teresa Kong
    Bhagavatheeswaran, Prabhu
    Novotny, James, Jr.
    Lestini, Brian
    Brahmer, Julie
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S253 - S253
  • [34] Phase II Trial of Talabostat and Docetaxel in Advanced Non-small Cell Lung Cancer
    Eager, R. M.
    Cunningham, C. C.
    Senzer, N.
    Richards, D. A.
    Raju, R. N.
    Jones, B.
    Uprichard, M.
    Nemunaitis, J.
    CLINICAL ONCOLOGY, 2009, 21 (06) : 464 - 472
  • [35] Update on targeted therapies for advanced non-small cell lung cancer: nivolumab in context
    Le, Alexander D.
    Alzghari, Saeed K.
    Jean, Gary W.
    La-Beck, Ninh M.
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2017, 13 : 223 - 236
  • [36] Docetaxel and non-small cell lung cancer
    Le Guen, Y
    Le Cesne, A
    BULLETIN DU CANCER, 2004, 91 (03) : 263 - 270
  • [37] Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)
    Rogado, J.
    Pacheco-Barcia, V.
    Fenor De la Maza, M. D.
    Serra, J. M.
    Toquero, P.
    Vera, B.
    Obispo, B.
    Mondejar, R.
    Ballesteros, A.
    Donnay, O.
    Colomer, R.
    Sanchez-Torres, J. M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1915 - S1916
  • [38] Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078)
    Lu, Shun
    Wang, Jie
    Cheng, Ying
    Mok, Tony
    Chang, Jianhua
    Zhang, Li
    Feng, Jifeng
    Tu, Hai-Yan
    Wu, Lin
    Zhang, Yiping
    Luft, Alexander
    Zhou, Jian-Ying
    Ma, Zhiyong
    Lu, You
    Hu, Chengping
    Shi, Yuankai
    Ying, Kejing
    Zhong, Hua
    Poddubskaya, Elena
    Soo, Ross A.
    Chia, Yee Hong
    Li, Ang
    Li, Amy
    Wu, Yi-Long
    LUNG CANCER, 2021, 152 : 7 - 14
  • [39] Cetuximab in advanced non-small cell lung cancer (NSCLC): the showdown?
    Sgambato, Assunta
    Casaluce, Francesca
    Maione, Paolo
    Rossi, Antonio
    Ciardiello, Fortunato
    Gridelli, Cesare
    JOURNAL OF THORACIC DISEASE, 2014, 6 (06) : 578 - 580
  • [40] Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153)
    Spigel, David R.
    McCleod, Michael
    Jotte, Robert M.
    Einhorn, Lawrence
    Horn, Leora
    Waterhouse, David M.
    Creelan, Ben
    Babu, Sunil
    Leighl, Natasha B.
    Chandler, Jason C.
    Couture, Felix
    Keogh, George
    Goss, Glenwood
    Daniel, Davey B.
    Garon, Edward B.
    Schwartzberg, Lee S.
    Sen, Rohini
    Korytowsky, Beata
    Li, Ang
    Aanur, Nivedita
    Hussein, Maen A.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (09) : 1628 - 1639
12345